Advertisement

Human Genetics

, 124:89 | Cite as

Calbindin 1, fibroblast growth factor 20, and α-synuclein in sporadic Parkinson’s disease

  • Ikuko Mizuta
  • Tatsuhiko Tsunoda
  • Wataru Satake
  • Yuko Nakabayashi
  • Masahiko Watanabe
  • Atsushi Takeda
  • Kazuko Hasegawa
  • Kenji Nakashima
  • Mitsutoshi Yamamoto
  • Nobutaka Hattori
  • Miho Murata
  • Tatsushi Toda
Original Investigation

Abstract

Parkinson’s disease (PD), one of the most common human neurodegenerative disorders, is characterized by the loss of dopaminergic neurons in the substantia nigra of the midbrain. Our recent case-control association study of 268 SNPs in 121 candidate genes identified α-synuclein (SNCA) as a susceptibility gene for sporadic PD (P = 1.7 × 10−11). We also replicated the association of fibroblast growth factor 20 (FGF20) with PD (P = 0.0089). To find other susceptibility genes, we added 34 SNPs to the previous screen. Of 302 SNPs in a total 137 genes, but excluding SNCA, SNPs in NDUFV2, FGF2, CALB1 and B2M showed significant association (P < 0.01; 882 cases and 938 control subjects). We replicated the association analysis for these SNPs in a second independent sample set (521 cases and 1,003 control subjects). One SNP, rs1805874 in calbindin 1 (CALB1), showed significance in both analyses (P = 7.1 × 10−5; recessive model). When the analysis was stratified relative to the SNCA genotype, the odds ratio of CALB1 tended to increase according to the number of protective alleles in SNCA. In contrast, FGF20 was significant only in the subgroup of SNCA homozygote of risk allele. CALB1 is a calcium-binding protein that widely is expressed in neurons. A relative sparing of CALB1-positive dopaminergic neurons is observed in PD brains, compared with CALB1-negative neurons. Our genetic analysis suggests that CALB1 is associated with PD independently of SNCA, and that FGF20 is associated with PD synergistically with SNCA.

Keywords

Dopaminergic Neuron Recessive Model Pairwise Linkage Disequilibrium Analysis Single Linkage Disequilibrium Block Potential Combinational Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We are grateful to the PD patients who participated in this study. We also thank Chiyomi Ito, Satoko Suzuki, and Dr. Yoshio Momose for help in performing the study; Drs. Akira Oka, Hidetoshi Inoko, and Katsushi Tokunaga for control samples; and Dr. Jennifer Logan for editing the manuscript. This work was supported by a grant from Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST); by the twenty-first Century COE program and KAKENHI (17019044 and 19590990), both from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; and by the Grant-in-Aid for “the Research Committee for the Neurodegenerative Diseases” of the Research on Measures for Intractable Diseases and Research Grant (H19-Genome-Ippan-001), all from the Ministry of Health, Labor, and Welfare of Japan.

Supplementary material

439_2008_525_MOESM1_ESM.doc (42 kb)
Supplementary Table 1 Summary of the First Screen of 34 SNPs (DOC 67 kb).
439_2008_525_MOESM2_ESM.doc (76 kb)
Supplementary Table 2 Association Analysis of the 26 SNPs (DOC 76 kb).
439_2008_525_MOESM3_ESM.doc (36 kb)
Supplementary Table 3 Haplotype Association Analysis in CALB1 region (DOC 36 kb).
439_2008_525_MOESM4_ESM.doc (35 kb)
Supplementary Table 4 Information of SNPs tagged by rs1805874 and four neighboring SNPs (DOC 68 kb).
439_2008_525_Fig2_ESM.jpg (27 kb)
Distribution of SNPs tagged by PD-associated SNP rs1805874 and four closely neighboring ones showing no association (rs2074596, rs12549239, rs12171665, and rs12541465). The five tag SNPs are presented by vertical lines. The SNPs tagged by rs1805874 are shown in red. All the SNP IDs are listed in Supplementary Table 4 (JPEG 26 kb).

References

  1. Bower JH, Maraganore DM, McDonnell SK, Rocca WA (1999) Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology 52:1214–1220PubMedGoogle Scholar
  2. Chard PS, Bleakman D, Christakos S et al (1993) Calcium buffering properties of calbindin D28k and parvalbumin in rat sensory neurones. J Physiol 472:341–357PubMedGoogle Scholar
  3. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 122:1437–1448PubMedCrossRefGoogle Scholar
  4. de Rijk MC, Tzourio C, Breteler MMB et al (1997) Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON collaborative study. J Neurol Neurosurg Psychiatry 62:10–15PubMedCrossRefGoogle Scholar
  5. Goedert M (2001) Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2:492–501PubMedCrossRefGoogle Scholar
  6. Haga H, Yamada R, Ohnishi Y et al (2002) Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190562 genetic variations in the human genome. J Hum Genet 47:605–610PubMedCrossRefGoogle Scholar
  7. Jande SS, Maler L, Lawson DEM (1981) Immunohistochemical mapping of vitamin D-dependent calcium-binding protein in brain. Nature 294:765–767PubMedCrossRefGoogle Scholar
  8. Maraganore DM, de Andrade M, Lesnick TG et al (2005) High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 77:685–693PubMedCrossRefGoogle Scholar
  9. Maraganore DM, de Andrade M, Elbaz A et al (2006) Collaborative analysis of α-synuclein gene promoter variability and Parkinson disease. JAMA 296:661–670PubMedCrossRefGoogle Scholar
  10. Mattson MP, Rychlik B, Chu C, Christakos S (1991) Evidence for calcium-reducing and excito-protective roles for the calcium-binding protein calbindin-D28 K in cultured hippocampal neurons. Neuron 6:41–51PubMedCrossRefGoogle Scholar
  11. McMahon A, Wong BS, Iacopino AM et al (1998) Calbindin-D28 K buffers intracellular calcium and promotes resistance to degeneration in PC12 cells. Mol Brain Res 54:56–63PubMedCrossRefGoogle Scholar
  12. Mizuta I, Satake W, Nakabayashi Y et al (2006) Multiple candidate gene analysis identifies α-synuclein as a susceptibility gene for sporadic Parkinson’s disease. Hum Mol Genet 15:1151–1158PubMedCrossRefGoogle Scholar
  13. Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci 28:57–87PubMedCrossRefGoogle Scholar
  14. Mueller JC, Fuchs J, Hofer A et al (2005) Multiple regions of α-synuclein are associated with Parkinson’s disease. Ann Neurol 57:535–541PubMedCrossRefGoogle Scholar
  15. Myhre R, Toft M, Kachergus J, Hulihan MM, Aasly JO, Klungland H, Farrer MJ (2008) Multiple alpha-synuclein gene polymorphisms are associated with Parkinson’s disease in a Norwegian population. Acta Neurol Scand (in press)Google Scholar
  16. Persechini A, Moncrief ND, Kretsinger RH (1989) The EF-hand family of calcium-modulated proteins. Trends Neurosci 12:462–467PubMedCrossRefGoogle Scholar
  17. Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047PubMedCrossRefGoogle Scholar
  18. Rascol O, Payoux P, Ory F et al (2003) Limitations of current Parkinson’s disease therapy. Ann Neurol 53(Suppl 3):S3–S12PubMedCrossRefGoogle Scholar
  19. Satake W, Mizuta I, Suzuki S et al (2007) Fibroblast growth factor 20 gene and Parkinson’s disease in the Japanese population. Neuroreport 18:937–940PubMedCrossRefGoogle Scholar
  20. Shults CW (2006) Lewy bodies. Proc Natl Acad Sci USA 103:1661–1668PubMedCrossRefGoogle Scholar
  21. Spillantini MG, Schmidt ML, Lee VM-Y et al (1997) α-Synuclein in Lewy bodies. Nature 388:839–840PubMedCrossRefGoogle Scholar
  22. The International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437:1299–1320CrossRefGoogle Scholar
  23. Thomas B, Beal MF (2007) Parkinson’s disease. Hum Mol Genet 16:R183–R194PubMedCrossRefGoogle Scholar
  24. Wang G, van der Walt JM, Mayhew G et al (2008) Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of α-synuclein. Am J Hum Genet 82:283–289PubMedCrossRefGoogle Scholar
  25. Warner TT, Schapira AH (2003) Genetic and environmental factors in the cause of Parkinson’s disease. Ann Neurol 53(Suppl 3):S16–S23PubMedCrossRefGoogle Scholar
  26. Wasserman RH, Corradino RA, Taylor AN (1968) Vitamin D-dependent calcium-binding protein. Purification and some properties. J Biol Chem 243:3978–3986PubMedGoogle Scholar
  27. Yamada T, McGeer PL, Baimbridge KG, McGeer EG (1990) Relative sparing in Parkinson’s disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res 526:303–307PubMedCrossRefGoogle Scholar
  28. Yenari MA, Minami M, Sun GH et al (2001) Calbindin D28K overexpression protects striatal neurons from transient focal cerebral ischemia. Stroke 32:1028–1035PubMedGoogle Scholar
  29. Zabetian CP, Hutter CM, Factor SA et al (2007) Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson’s disease. Ann Neurol 62:137–144PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Ikuko Mizuta
    • 1
    • 2
  • Tatsuhiko Tsunoda
    • 3
  • Wataru Satake
    • 1
  • Yuko Nakabayashi
    • 1
    • 2
  • Masahiko Watanabe
    • 4
  • Atsushi Takeda
    • 5
  • Kazuko Hasegawa
    • 6
  • Kenji Nakashima
    • 7
  • Mitsutoshi Yamamoto
    • 8
  • Nobutaka Hattori
    • 9
  • Miho Murata
    • 10
  • Tatsushi Toda
    • 1
    • 2
  1. 1.Division of Clinical Genetics, Department of Medical GeneticsOsaka University Graduate School of MedicineSuitaJapan
  2. 2.Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology AgencySaitamaJapan
  3. 3.Laboratory for Medical Informatics, SNP Research CenterThe Institute of Physical and Chemical Research (RIKEN)YokohamaJapan
  4. 4.Department of Neurology, Graduate School of Comprehensive Human SciencesUniversity of TsukubaTsukubaJapan
  5. 5.Division of Neurology, Department of NeuroscienceTohoku University Graduate School of MedicineSendaiJapan
  6. 6.Department of NeurologyNational Hospital Organization, Sagamihara National HospitalSagamiharaJapan
  7. 7.Department of NeurologyTottori University Faculty of MedicineYonagoJapan
  8. 8.Department of NeurologyKagawa Prefectural Central HospitalTakamatsuJapan
  9. 9.Department of NeurologyJuntendo University School of MedicineTokyoJapan
  10. 10.Department of NeurologyMusashi Hospital, National Center of Neurology and PsychiatryKodairaJapan

Personalised recommendations